Llamas-Ostos AN, Prieto-Vargas V, Arjona-Bojorquez RI, Bautista-Fuentes C, Apellaniz-Campo AG, Fuentes-Calvo KJ, García-Cordova CE, Martínez-Martínez G

Language: Spanish
References: 10
Page: 189-193
PDF size: 1750.33 Kb.

ABSTRACT

Hunter syndrome (mucopolysaccharidosis type II) is a genetic lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase, leading to progressive accumulation of glycosaminoglycans. Facial hypertrophic scars have not been described as initial indications of this condition. We present the case of a male patient with confirmed diagnosis through skin biopsy, histopathological findings and enzymatic analysis, whose initial clinical revelation was severe facial hypertrophic scarring following nodulocystic acne. Treatment consisted of complete lesion resection, coverage with a split-thickness autologous skin graft and adjuvant use of platelet-rich plasma and nanofat. In addition to this, the patient used facial compression garments in the immediate and late postoperative period to control the scarring. At six-month follow-up, complete graft integration was observed, with no recurrence and satisfactory aesthetic and functional results. This combined surgical approach may represent a safe and effective alternative in cases of pathological scarring associated with metabolic diseases.

REFERENCES

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA. The Online Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2019.

2. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008; 167 (3): 267-277.

3. Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Muñoz V et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008;121(2):e377-e386.

4. Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol. 1983; 25 (4): 481-489.

5. Robles DT, Berg D. Abnormal wound healing: keloids. Clin Dermatol. 2007; 25 (1): 26-32.

6. Ting W, Chong Y, Xu J, Huang J, Yu N, Liu Z. Treatment of keloids using plasma skin regeneration combined with radiation therapy under the evaluation of patient and observer scar assessment scale. Clin Cosmet Investig Dermatol. 2021; 14: 981-989. doi: 10.2147/CCID.S321348.

7. Rigotti G, Marchi A, Galie M, Baroni G, Benati D, Krampera M et al. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells. Plast Reconstr Surg. 2007; 119 (5): 1409-1422.

8. Panagaki T, Randi EB, Szabo C. Role of Hydrogen Sulfide and 3-Mercaptopyruvate Sulfurtransferase in the Regulation of the Endoplasmic Reticulum Stress Response in Hepatocytes. Biomolecules. 2020; 10 (12): 1692. doi: 10.3390/biom10121692

9. Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci. 2017; 18 (3): 606. doi: 10.3390/ijms18030606.

10. Tremolada C, Colombo V, Ventura C. Adipose tissue and mesenchymal stem cells: state of the art and lipogems^® technology development. Curr Stem Cell Rep. 2016; 2 (3): 304-312. doi: 10.1007/s40778-016-0053-5.